FT
CRNX

Fiduciary Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fiduciary Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Buy
12,631
+3,252
+35% +$121K 0.01% 624
2026
Q1 		$341K Buy
9,379
+482
+5% +$21.5K ﹤0.01% 697
2025
Q4 		$414K Buy
8,897
+1,477
+20% +$65.8K ﹤0.01% 623
2025
Q3 		$309K Hold
7,420
– – ﹤0.01% 694
2025
Q2 		$213K Buy
7,420
+525
+8% +$16.2K ﹤0.01% 787
2025
Q1 		$231K Buy
+6,895
New +$258K ﹤0.01% 746

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiduciary Trust's CRNX Position: Q2 2026 in Review

Fiduciary Trust increased its Crinetics Pharmaceuticals (CRNX) stake by 35% in Q2 2026, buying an estimated $121K and bringing the position to 12,631 shares worth $473K. The position accounts for 0.01% of the portfolio, ranked #624.

Fiduciary Trust first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Fiduciary Trust held 12,631 shares of Crinetics Pharmaceuticals worth $473K as of Q2 2026.
  • Fiduciary Trust bought 3,252 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $121K.
  • Crinetics Pharmaceuticals made up 0.01% of Fiduciary Trust's portfolio in Q2 2026, its #624 holding.
  • Fiduciary Trust first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.